Skip to main content
SpringerLink
Log in

Comparison of Clopidogrel, Prasugrel and Ticagrelor Response of Patients by PFA-100-Innovance Test Results

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Devices such as stents and flow diverters require the use of safe and fast antiplatelet therapy. We aimed to compare the responses to clopidogrel, prasugrel, and ticagrelor by assessing the Platelet Function Analysis (PFA-100)-Innovance test results of patients undergoing endovascular stenting to determine their resistance rates. Sixty-one women and 55 men, aged 18–87 years, were included in this study. Patients were divided into three groups: clopidogrel treatment, prasugrel treatment, and ticagrelor treatment. The systemic diseases of the patients, especially hypertension and diabetes, were recorded. The test results were evaluated according to the results for the collagen/epinephrine (COL-EPI), collagen/adenosine (COL-ADP), and P2Y results. The PFA-100-Innovance results for COL-EPI and P2Y were significantly higher for patients treated with prasugrel and ticagrelor compared with patients treated with clopidogrel (COL-EPI, p = 0.001; P2Y, p = 0.001). Clopidogrel resistance was identified in 31 patients (26.7%), and prasugrel resistance was identified in 4 patients (3.4%). Ticagrelor resistance was not detected. Therefore, 30.1% of patients were classified as drug-resistant. Perioperative bleeding was not detected in any patient. Hypertension was the most common disease recorded for patients being treated for cerebral aneurysm, and diabetes was the most common disease recorded for patients who underwent peripheral artery stenting (p = 0.002). Potent antiplatelet agents, such as prasugrel and ticagrelor, have a low rate of resistance but are associated with an increased bleeding risk. Thus, the choice of a suitable drug during the treatment window remains a critical factor when determining treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability and Materials

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

  1. Rolling CC, Tomada J, Frölich AM et al (2020) Comparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100® in patients undergoing neuroendovascular procedures. Clin Chem Lab Med 59(2):383–392. https://doi.org/10.1515/cclm-2020-0737

    Article  CAS  PubMed  Google Scholar 

  2. Giossi A, Pezzini A, Del Zotto E et al (2010) Advances in antiplatelet therapy for stroke prevention: the new P2Y12 antagonists. Curr Drug Targets 11(3):380–391. https://doi.org/10.2174/138945010790711987

    Article  CAS  PubMed  Google Scholar 

  3. Siller-Matula JM, Krumphuber J, Jilma B (2010) Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 159(3):502–517. https://doi.org/10.1111/j.1476-5381.2009.00555.x

    Article  CAS  PubMed  Google Scholar 

  4. Alvitigala BY, Gooneratne LV, Constantine GR et al (2020) Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy. Pharmacol Res Perspect 8(6):e00686. https://doi.org/10.1002/prp2.686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cattaneo M (2011) Resistance to anti-platelet agents. Thromb Res 127(Suppl 3):S61-63. https://doi.org/10.1016/s0049-3848(11)70017-2

    Article  CAS  PubMed  Google Scholar 

  6. Birkeland K, Parra D, Rosenstein R (2010) Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. J Blood Med 1:197–219. https://doi.org/10.2147/jbm.S9650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Russeau AP, Vall H, Manna B (2021) Bleeding Time. In: StatPearls. StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC., Treasure Island (FL)

  8. Dovlatova N, Heptinstall S (2018) Platelet aggregation measured by single-platelet counting and using PFA-100 devices. Platelets 29(7):656–661. https://doi.org/10.1080/09537104.2018.1492109

    Article  CAS  PubMed  Google Scholar 

  9. Favaloro EJ (2017) Clinical utility of closure times using the platelet function analyzer-100/200. Am J Hematol 92(4):398–404. https://doi.org/10.1002/ajh.24620

    Article  CAS  PubMed  Google Scholar 

  10. Le Quellec S, Bordet JC, Negrier C et al (2016) Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature. Thrombosis Haemostasis 116(4):638–650. https://doi.org/10.1160/TH15-11-0870

    Article  PubMed  Google Scholar 

  11. Tsantes A, Ikonomidis I, Papadakis I et al (2012) Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance. Platelets 23(6):481–489. https://doi.org/10.3109/09537104.2012.689037

    Article  CAS  PubMed  Google Scholar 

  12. Taylor LI, Dickerson JC, Dambrino RJ et al (2017) Platelet testing in flow diversion: a review of the evidence. Neurosurg Focus 42(6):E5. https://doi.org/10.3171/2017.3.FOCUS1746

    Article  PubMed  Google Scholar 

  13. Winter MP, Grove EL, De Caterina R et al (2017) Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother 3(4):221–234. https://doi.org/10.1093/ehjcvp/pvw044

    Article  PubMed  Google Scholar 

  14. Siller-Matula JM, Hintermeier A, Kastner J et al (2016) Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. Vascul Pharmacol 79:6–10. https://doi.org/10.1016/j.vph.2016.01.003

    Article  CAS  PubMed  Google Scholar 

  15. Alakbarzade V, Huang X, Ster IC et al (2020) High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: Systematic review and meta-analysis. J Stroke Cerebrovasc Dis 29(7):104877. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104877

    Article  PubMed  Google Scholar 

  16. Fiolaki A, Katsanos AH, Kyritsis AP et al (2017) High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: a systematic review and meta-analysis. J Neurol Sci 376:112–116. https://doi.org/10.1016/j.jns.2017.03.010

    Article  CAS  PubMed  Google Scholar 

  17. Dalal JJ, Digrajkar A, Gandhi A (2016) Oral antiplatelet therapy and platelet inhibition: an experience from a tertiary care center. Indian Heart J 68(5):624–631. https://doi.org/10.1016/j.ihj.2015.12.022

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kim MJ, Patel P, Vyas N et al (2020) A 70-year-old female with unexpected platelet function testing results. Lab Med 51(3):310–314. https://doi.org/10.1093/labmed/lmz070

    Article  PubMed  Google Scholar 

  19. Atallah E, Saad H, Bekelis K et al (2018) The use of alternatives to clopidogrel in flow-diversion treatment with the Pipeline embolization device. J Neurosurg 129(5):1130–1135. https://doi.org/10.3171/2017.5.JNS162663

    Article  CAS  PubMed  Google Scholar 

  20. Cagnazzo F, Perrini P, Lefevre PH et al (2019) Comparison of prasugrel and clopidogrel used as antiplatelet medication for endovascular treatment of unruptured intracranial aneurysms: a meta-analysis. AJNR Am J Neuroradiol 40(4):681–686. https://doi.org/10.3174/ajnr.A6004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Warlo EMK, Arnesen H, Seljeflot I (2019) A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease. Thromb J 17:11. https://doi.org/10.1186/s12959-019-0197-5

    Article  PubMed  PubMed Central  Google Scholar 

  22. Yu ES, Jeon MJ, Kang KW et al (2020) The role of platelet function analyzer-200 in predicting perioperative bleeding risk. Korean J Intern Med 35(5):1199–1209. https://doi.org/10.3904/kjim.2019.112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Belkacemi M, Merad Y (2021) Variables that Influence platelet function analyzer-100™ closure times in healthy algerian adults. Int J Appl Basic Med Res 11(3):154–159. https://doi.org/10.4103/ijabmr.IJABMR_532_20

    Article  PubMed  PubMed Central  Google Scholar 

  24. Mshelbwala FS, Hugenberg DW, Kreutz RP (2020) Impact of routine platelet reactivity testing with verifynow assay on antiplatelet choice after percutaneous coronary intervention. Clin Pharmacol Adv Appl 12:35–41. https://doi.org/10.2147/CPAA.S242675

    Article  CAS  Google Scholar 

  25. Podlasek A, Al Sultan AA, Assis Z et al (2020) Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis. J Neurointerv Surg 12(2):148–155. https://doi.org/10.1136/neurintsurg-2019-014996

    Article  PubMed  Google Scholar 

Download references

Funding

No funding was received for this study.

Author information

Authors and Affiliations

  1. Department of Radiology, Baskent University Alanya Application and Research Center, Antalya, Turkey

    Abdullah Sukun

  2. Department of Biochemistry, Antalya Training and Research Hospital, Antalya, Turkey

    Feyza Tekeli

  3. Institut für Diagnostische und Interventionelle Radiologie, Kinder- und Neuroradiologie, Universitätsmedizin Rostock, Rostock, Germany

    Abdullah Sukun

  4. Exchange Programme for Fellowships, European School of Radiology (ESOR), Vienna, Austria

    Abdullah Sukun

Authors
  1. Abdullah Sukun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Feyza Tekeli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdullah Sukun.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sukun, A., Tekeli, F. Comparison of Clopidogrel, Prasugrel and Ticagrelor Response of Patients by PFA-100-Innovance Test Results. Indian J Hematol Blood Transfus 39, 294–299 (2023). https://doi.org/10.1007/s12288-022-01600-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-022-01600-7

Keywords

Search

Navigation